Search research articles
Contact Us
Filters
Showing results (11-20 of 272) with videos related to
Page
of 28
Sort By:
Clinical Lung Cancer
|
April 6, 2017
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
Oscar Juan, Sanjay Popat
Anti-Cancer Drugs
|
March 5, 2005
Chemotherapy strategies in the treatment of small cell lung cancer
Sanjay Popat, Mary O'Brien
Journal of Thoracic Disease
|
April 2, 2014
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC
Fiona McDonald, Sanjay Popat
Therapeutic Advances in Respiratory Disease
|
March 25, 2015
The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
Alexandra Pender, Sanjay Popat
Cancer Treatment Reviews
|
August 16, 2021
Pleural mesothelioma (PM) - The status of systemic therapy
Wanyuan Cui, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)
|
November 20, 2016
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
Oscar Juan, Sanjay Popat
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2023
Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
Anna Minchom, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2005
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
Sanjay Popat, Richard S Houlston
Journal of the National Cancer Institute
|
December 22, 2005
Re: Reporting recommendations for tumor marker prognostic studies (REMARK)
Sanjay Popat, Richard S Houlston
Pharmacogenomics and Personalized Medicine
|
October 4, 2014
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Timothy A Yap, Sanjay Popat
Page
of 28
Search research articles
Search
Showing results (11-20 of 272) with videos related to
Sort By:
Page
of 28
Clinical Lung Cancer
|
April 6, 2017
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
Oscar Juan, Sanjay Popat
Anti-Cancer Drugs
|
March 5, 2005
Chemotherapy strategies in the treatment of small cell lung cancer
Sanjay Popat, Mary O'Brien
Journal of Thoracic Disease
|
April 2, 2014
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC
Fiona McDonald, Sanjay Popat
Therapeutic Advances in Respiratory Disease
|
March 25, 2015
The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
Alexandra Pender, Sanjay Popat
Cancer Treatment Reviews
|
August 16, 2021
Pleural mesothelioma (PM) - The status of systemic therapy
Wanyuan Cui, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)
|
November 20, 2016
Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
Oscar Juan, Sanjay Popat
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2023
Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
Anna Minchom, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2005
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
Sanjay Popat, Richard S Houlston
Journal of the National Cancer Institute
|
December 22, 2005
Re: Reporting recommendations for tumor marker prognostic studies (REMARK)
Sanjay Popat, Richard S Houlston
Pharmacogenomics and Personalized Medicine
|
October 4, 2014
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Timothy A Yap, Sanjay Popat
Page
of 28